Amoéba

Regulatory Filings • Aug 10, 2022

PRESS RELEASE

US EPA about to approve Amoéba's biocide for use in closed cooling systems

Lyon (France), August 10th , 2022 - 17h45 - AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, informs that the United States Environmental Protection Agency (US EPA) has made a positive pre-decisional determination following its assessment of the application dossier for the use of Willaertia magna C2c Maky as a biocidal active ingredient in cooling systems.

The US EPA has concluded that the amoeba Willaertia magna C2c Maky and the BIOMEBA products containing it can be authorized on the United States territory for a biocidal use in closed cooling systems, for the control of microbial slime (bioslime), microbially induced corrosion and general microbial flora in cooling towers waters.

Based on the last administrative steps required by the US EPA to finalize the procedure, the issuance of the marketing authorization of the products is expected by the end of 2022 at the latest.

"This is historic news that has just been sent to us by the US EPA. Amoéba has been legitimized in its application for the use of a microorganism in the treatment of bacterial risk in water. We will now refine our analysis of the market potential for this type of closed systems. We hope that the pragmatism of North American regulatory agencies will one day inspire European agencies. This decision adds a very positive note to the worldwide interest already in place for our biocontrol application and will influence the company's future development.", says Fabrice Plasson, CEO of Amoéba.

About Amoéba :

Amoéba's ambition is to become the world leader in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (3). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (4) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The company is currently in the testing phase for biocidal and phytosanitary applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-nature.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

(4): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

Contacts: Amoéba Valérie FILIATRE Deputy General Manager +33 4 26 69 16 00 v.filiatre@amoeba-nature.com

Disclaimer

Calyptus Investor & Press Relations Nicolas HELIN / Mathieu CALLEUX +33 1 53 65 37 90 /91 amoeba@calyptus.net

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forwardlooking statements.